版本:
中国

BRIEF-Aptevo Therapeutics says next generation ADAPTIR bispecific antibody candidates show potent immune activation

April 3 Aptevo Therapeutics Inc

* Aptevo therapeutics’ next generation adaptir™ bispecific antibody candidates show potent immune activation

* Aptevo -new data highlight potent in vitro and in vivo activity of apvo436 and apvo437 at inducing rtcc in preclinical models of acute myelogenous leukemia Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐